Health Care • Biotechnology: Pharmaceutical Preparations
$3.50 ▲ +0.07
(+2.04%)
MKT CAP: $1.13B • VOL: 2.28M
52W L $2 52W H $7
MNKD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $349.0M | $285.5M | $199.0M |
| YoY Revenue Growth % | +22.2% | +43.5% | — |
| Gross Profit | $322.2M | $268.1M | — |
| Gross Margin % | 92.3% | 93.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $38.8M | $72.6M | $8.7M |
| Operating Margin % | 11.1% | 25.4% | 4.4% |
| Net Income (GAAP) | $5.9M | $27.6M | -$11.9M |
| EBITDA (Normalized) | $42.5M | $80.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $18.3M | $42.5M | $34.1M |
| Capital Expenditures (CapEx) | $4.6M | $9.7M | — |
| Free Cash Flow (FCF) | $13.7M | $32.8M | $34.1M |
| FCF Margin % | 3.9% | 11.5% | 17.1% |
| Return on Invested Capital (ROIC %) | 95.0% | 95.0% | — |
| Cash & Short-Term Equivalents | $74.9M | $46.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$51.0M | -$78.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MNKD.